Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
83% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. SGEN: No Debt )
SGEN' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.48
SGEN's Equity to Asset is ranked higher than
60% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGEN: 0.48 )
SGEN' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.97
Current: 0.48

0.36
0.97
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
96% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
SGEN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 9.67
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -23.35
SGEN's Operating margin (%) is ranked higher than
76% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. SGEN: -23.35 )
SGEN' s 10-Year Operating margin (%) Range
Min: -9958.59   Max: -23.35
Current: -23.35

-9958.59
-23.35
Net-margin (%) -23.22
SGEN's Net-margin (%) is ranked higher than
75% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. SGEN: -23.22 )
SGEN' s 10-Year Net-margin (%) Range
Min: -7917.17   Max: -23.22
Current: -23.22

-7917.17
-23.22
ROE (%) -27.16
SGEN's ROE (%) is ranked higher than
68% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. SGEN: -27.16 )
SGEN' s 10-Year ROE (%) Range
Min: -108.2   Max: -23.78
Current: -27.16

-108.2
-23.78
ROA (%) -12.92
SGEN's ROA (%) is ranked higher than
74% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. SGEN: -12.92 )
SGEN' s 10-Year ROA (%) Range
Min: -45.55   Max: -11.41
Current: -12.92

-45.55
-11.41
ROC (Joel Greenblatt) (%) -154.12
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. SGEN: -154.12 )
SGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -878.7   Max: -154.12
Current: -154.12

-878.7
-154.12
Revenue Growth (%) 27.80
SGEN's Revenue Growth (%) is ranked higher than
92% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. SGEN: 27.80 )
SGEN' s 10-Year Revenue Growth (%) Range
Min: 7.3   Max: 157.1
Current: 27.8

7.3
157.1
EBITDA Growth (%) -11.10
SGEN's EBITDA Growth (%) is ranked higher than
73% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. SGEN: -11.10 )
SGEN' s 10-Year EBITDA Growth (%) Range
Min: -30.2   Max: 18
Current: -11.1

-30.2
18
EPS Growth (%) -8.20
SGEN's EPS Growth (%) is ranked higher than
77% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. SGEN: -8.20 )
SGEN' s 10-Year EPS Growth (%) Range
Min: -34   Max: 27.9
Current: -8.2

-34
27.9
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SGEN Guru Trades in Q1 2013

Manning & Napier Advisors, Inc 492,200 sh (+46.89%)
RS Investment Management 398,920 sh (+1.52%)
Steven Cohen Sold Out
PRIMECAP Management 10,429,099 sh (-0.89%)
Columbia Wanger 8,625,000 sh (-3.8%)
Jim Simons 219,613 sh (-47.07%)
» More
Q2 2013

SGEN Guru Trades in Q2 2013

Steven Cohen 35,241 sh (New)
Jim Simons 402,013 sh (+83.06%)
Manning & Napier Advisors, Inc 532,360 sh (+8.16%)
PRIMECAP Management 10,887,919 sh (+4.4%)
RS Investment Management Sold Out
Columbia Wanger 8,125,000 sh (-5.8%)
» More
Q3 2013

SGEN Guru Trades in Q3 2013

Steven Cohen 44,608 sh (+26.58%)
PRIMECAP Management 10,887,000 sh (-0.01%)
Columbia Wanger 7,547,000 sh (-7.11%)
Jim Simons 339,213 sh (-15.62%)
Manning & Napier Advisors, Inc 381,140 sh (-28.41%)
» More
Q4 2013

SGEN Guru Trades in Q4 2013

PRIMECAP Management 10,953,400 sh (+0.61%)
Manning & Napier Advisors, Inc 369,210 sh (-3.13%)
Columbia Wanger 6,701,000 sh (-11.21%)
Steven Cohen 28,354 sh (-36.44%)
Jim Simons 126,013 sh (-62.85%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2011-06-30 Add 21.21%0.05%$15 - $21.34 $ 38.84116%9572853
PRIMECAP Management 2011-03-31 Add 29.25%0.04%$13.95 - $17.23 $ 38.84152%7897953
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 20.80
SGEN's P/B is ranked lower than
72% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. SGEN: 20.80 )
SGEN' s 10-Year P/B Range
Min: 1.64   Max: 29.21
Current: 20.8

1.64
29.21
P/S 17.50
SGEN's P/S is ranked lower than
59% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. SGEN: 17.50 )
SGEN' s 10-Year P/S Range
Min: 9.98   Max: 64.56
Current: 17.5

9.98
64.56
EV-to-EBIT 15.90
SGEN's EV-to-EBIT is ranked higher than
67% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. SGEN: 15.90 )
SGEN' s 10-Year EV-to-EBIT Range
Min: 68.7   Max: 92.9
Current: 15.9

68.7
92.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 39.60
SGEN's Price/Net Cash is ranked lower than
82% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. SGEN: 39.60 )
SGEN' s 10-Year Price/Net Cash Range
Min: 3.73   Max: 45.6
Current: 39.6

3.73
45.6
Price/Net Current Asset Value 30.30
SGEN's Price/Net Current Asset Value is ranked lower than
76% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. SGEN: 30.30 )
SGEN' s 10-Year Price/Net Current Asset Value Range
Min: 3.68   Max: 35.63
Current: 30.3

3.68
35.63
Price/Tangible Book 20.70
SGEN's Price/Tangible Book is ranked lower than
83% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. SGEN: 20.70 )
SGEN' s 10-Year Price/Tangible Book Range
Min: 2.04   Max: 21.22
Current: 20.7

2.04
21.22
Price/Median PS Value 0.70
SGEN's Price/Median PS Value is ranked higher than
85% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SGEN: 0.70 )
SGEN' s 10-Year Price/Median PS Value Range
Min: 0.55   Max: 24.78
Current: 0.7

0.55
24.78
Forward Rate of Return (Yacktman) -16.33
SGEN's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SGEN: -16.33 )
SGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.8   Max: 2.6
Current: -16.33

1.8
2.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SGT.Germany
Seattle Genetics, Inc., a Delaware corporation was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. On August 19, 2011, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of ADCETRISTM, or brentuximab vedotin, in two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Company's proprietary technology. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has four clinical-stage ADC programs, which consist of SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A, as well as several preclinical product candidates, including SGN-CD33A and SGN-LIV1A. The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, pre-market approval, manufacture, marketing and distribution of biopharmaceutical products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide